Pfizer Reports Plans for Major Boost in Outsourcing, Personnel Cuts
ePT--the Electronic Newsletter of Pharmaceutical Technology
Pfizer?s restructuring plans reportedly include major investments in outsourced manufacturing operations, production facility closures, and personnel reductions.
Hong Kong (Nov. 30)-Pfizer’s restructuring plans reportedly include major investments in outsourced manufacturing operations, production facility closures, and personnel reductions (Drug Industry Daily, Dec. 3). During an investor meeting in Hong Kong, Martin Mackay, president of Pfizer’s global R&D, said the company is aiming to outsource 30% of its manufacturing activities to lower-cost regions such as Asia, a significant jump from it’s current value of 15%.
According to industry reports, Pfizer plans to close nearly 45 production facilities and reduce its personnel by 10%.
Declining sales stemming from competitive brands and generics, especially for its “Lipitor” (atorvastatin calcium) and “Norvasc” (amlodipine besylate) products, have been cited as the main factors in the company’s need for restructuring.
A webcast and copy of the presentation can be accessed here.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
